001023080 001__ 1023080
001023080 005__ 20250204113805.0
001023080 0247_ $$2doi$$a10.1111/bph.16309
001023080 0247_ $$2ISSN$$a0007-1188
001023080 0247_ $$2ISSN$$a0366-0826
001023080 0247_ $$2ISSN$$a1476-5381
001023080 0247_ $$2ISSN$$a2056-8177
001023080 0247_ $$2datacite_doi$$a10.34734/FZJ-2024-01653
001023080 0247_ $$2pmid$$a38157867
001023080 0247_ $$2WOS$$aWOS:001158587800001
001023080 037__ $$aFZJ-2024-01653
001023080 082__ $$a610
001023080 1001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b0
001023080 245__ $$aAn orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain
001023080 260__ $$aMalden, MA$$bWiley$$c2024
001023080 3367_ $$2DRIVER$$aarticle
001023080 3367_ $$2DataCite$$aOutput Types/Journal article
001023080 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738246180_31341
001023080 3367_ $$2BibTeX$$aARTICLE
001023080 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001023080 3367_ $$00$$2EndNote$$aJournal Article
001023080 520__ $$aAbstractBackground and Purpose:Neuropathic pain affects up to 10% of the global popula-tion and is caused by an injury or a disease affecting the somatosensory, peripheral,or central nervous system. NP is characterized by chronic, severe and opioid-resistantproperties. Therefore, its clinical management remains very challenging. The N-typevoltage-gated calcium channel, Cav2.2, is a validated target for therapeutic interven-tion in chronic and neuropathic pain. The conotoxin ziconotide (Prialt®) is an FDA-approved drug that blocks Cav2.2 channel but needs to be administered intrathecally.Thus, although being principally efficient, the required application route is very muchin disfavour.Experimental Approach and Key Results:Here, we describe an orally available drugcandidate, RD2, which competes with ziconotide binding to Cav2.2 at nanomolarconcentrations and inhibits Cav2.2 almost completely reversible. Other voltage-gatedcalcium channel subtypes, like Cav1.2 and Cav3.2, were affected by RD2 only at con-centrations higher than 10μM. Data from sciatic inflammatory neuritis rat modeldemonstrated thein vivoproof of concept, as low-dose RD2 (5 mgkg-1) administeredorally alleviated neuropathic pain compared with vehicle controls. High-dose RD2(50 mgkg-1) was necessary to reduce pain sensation in acute thermal responseassessed by the tail flick test.Conclusions and Implications:Taken together, these results demonstrate that RD2has antiallodynic properties. RD2 is orally available, which is the most convenientapplication form for patients and caregivers. The surprising and novel result fromstandard receptor screens opens the room for further optimization into new promis-ing drug candidates, which address an unmet medical need.
001023080 536__ $$0G:(DE-HGF)POF4-5244$$a5244 - Information Processing in Neuronal Networks (POF4-524)$$cPOF4-524$$fPOF IV$$x0
001023080 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001023080 7001_ $$0P:(DE-Juel1)165956$$aGuzman, Gustavo A.$$b1
001023080 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b2
001023080 7001_ $$0P:(DE-HGF)0$$aKletke, Olaf$$b3
001023080 7001_ $$0P:(DE-Juel1)180939$$aWollert, Esther$$b4
001023080 7001_ $$0P:(DE-Juel1)171922$$aGering, Ian$$b5
001023080 7001_ $$0P:(DE-Juel1)144626$$aJürgens, Dagmar$$b6
001023080 7001_ $$0P:(DE-HGF)0$$aBreitkreutz, Jörg$$b7
001023080 7001_ $$00000-0003-3336-1710$$aStark, Holger$$b8
001023080 7001_ $$0P:(DE-HGF)0$$aBeck-Sickinger, Annette G.$$b9
001023080 7001_ $$0P:(DE-HGF)0$$aKlöcker, Nikolaj$$b10
001023080 7001_ $$0P:(DE-Juel1)151357$$aHidalgo, Patricia$$b11
001023080 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b12$$eCorresponding author
001023080 773__ $$0PERI:(DE-600)2029728-2$$a10.1111/bph.16309$$gp. bph.16309$$n12$$p1734-1756$$tBritish journal of pharmacology$$v181$$x0007-1188$$y2024
001023080 8564_ $$uhttps://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.pdf$$yOpenAccess
001023080 8564_ $$uhttps://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.gif?subformat=icon$$xicon$$yOpenAccess
001023080 8564_ $$uhttps://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
001023080 8564_ $$uhttps://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
001023080 8564_ $$uhttps://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
001023080 8767_ $$d2024-02-16$$eHybrid-OA$$jDEAL
001023080 909CO $$ooai:juser.fz-juelich.de:1023080$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC_DEAL$$popen_access$$popenaire
001023080 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b0$$kFZJ
001023080 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)165956$$aForschungszentrum Jülich$$b1$$kFZJ
001023080 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b2$$kFZJ
001023080 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180939$$aForschungszentrum Jülich$$b4$$kFZJ
001023080 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171922$$aForschungszentrum Jülich$$b5$$kFZJ
001023080 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144626$$aForschungszentrum Jülich$$b6$$kFZJ
001023080 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)151357$$aForschungszentrum Jülich$$b11$$kFZJ
001023080 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b12$$kFZJ
001023080 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5244$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
001023080 9141_ $$y2024
001023080 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001023080 915pc $$0PC:(DE-HGF)0120$$2APC$$aDEAL: Wiley 2019
001023080 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-22
001023080 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-22
001023080 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
001023080 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-08-22$$wger
001023080 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-22
001023080 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001023080 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-31
001023080 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-31
001023080 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-31
001023080 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-31
001023080 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-31
001023080 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-31
001023080 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J PHARMACOL : 2022$$d2024-12-31
001023080 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-31
001023080 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-31
001023080 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J PHARMACOL : 2022$$d2024-12-31
001023080 920__ $$lyes
001023080 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
001023080 980__ $$ajournal
001023080 980__ $$aVDB
001023080 980__ $$aI:(DE-Juel1)IBI-7-20200312
001023080 980__ $$aAPC
001023080 980__ $$aUNRESTRICTED
001023080 9801_ $$aAPC
001023080 9801_ $$aFullTexts